VTAE 17.85 Vitae Pharmaceuticals Inc $VTAE Hit a 52 week

New Post Public Reply Private Reply Replies (0) Message Board

Nov 13, 2014 at 2:22 PM

VTAE 17.85 Vitae Pharmaceuticals Inc $VTAE Hit a 52 week high of 18.30 Closing the day 09:45 at 17.85 +0.64 +3.72% With a day low of 17.00 and a total volume of 54,801.

VTAE Recent Posts: http://investorshangout.com/Vitae-Pharmaceuti...TAE-90576/

VTAE Vitae Pharmaceuticals Inc Recent Headline News

Vitae Pharmaceuticals EPS of -$1.06
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 4:15PM CST

VTAE: 15.86 (-1.35)

Vitae Pharmaceuticals Reports Third Quarter 2014 Operating and Financial Results
GlobeNewswire - Wed Nov 12, 3:06PM CST
Vitae Pharmaceuticals, Inc. (Nasdaq:VTAE), a clinical-stage biotechnology company, reported today its operating and financial results for the third quarter ended September 30, 2014.
VTAE: 15.86 (-1.35)

Vitae Pharmaceuticals to Present at Stifel 2014 Healthcare Conference
GlobeNewswire - Wed Nov 12, 7:00AM CST
Vitae Pharmaceuticals, Inc. (Nasdaq:VTAE), a clinical-stage biotechnology company, today announced that Jeffrey Hatfield, President and Chief Executive Officer, will present a company overview at the Stifel 2014 Healthcare Conference on Wednesday, November 19, 2014 at 4:45 p.m. EST in New York City.
VTAE: 15.86 (-1.35)

Global Chronic Kidney Disease (Chronic Renal Failure) Therapeutics Pipeline Report H2 2014 - Analysis of 27 Companies & 39 Drug Profiles
M2 - Mon Nov 10, 10:32AM CST
Research and Markets (http://www.researchandmarkets.com/research/n5l8s3/chronic_kidney) has announced the addition of the "Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Kidney Disease (Chronic Renal Failure), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Kidney Disease (Chronic Renal Failure) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Hospira, Inc. - AstraZeneca PLC - Eli Lilly and Company - Quark Pharmaceuticals, Inc. - Astellas Pharma Inc. - OPKO Health, Inc. - Toray Industries, Inc. - Evotec AG - NPS Pharmaceuticals, Inc. - La Jolla Pharmaceutical Company - Alexion Pharmaceuticals, Inc. - AFFiRiS AG - Acceleron Pharma, Inc. - Nippon Zoki Pharmaceutical Co., Ltd. - Catabasis Pharmaceuticals, Inc. - Angion Biomedica Corp. - Concert Pharmaceuticals, Inc. - Intercept Pharmaceuticals, Inc. - Vitae Pharmaceuticals, Inc. - TRACON Pharmaceuticals, Inc. - Stelic Institute & Co. - Vicore Pharma AB - Otsuka Holdings Co., Ltd. - Sphaera Pharma Pvt. Ltd. - Multi Gene Vascular Systems Ltd - Bio-inRen - Red Glead Discovery AB For more information visit http://www.researchandmarkets.com/research/n5...nic_kidney
VTAE: 15.86 (-1.35), LLY: 67.57 (+0.17), CNCE: 13.49 (+0.66), OPK: 8.36 (-0.01), AZN: 74.53 (+0.27), ALXN: 192.68 (-1.01), ICPT: 162.72 (-0.24), NPSP: 29.88 (+0.71), XLRN: 38.03 (+4.24)

Vitae Pharma reports November 12
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 10:04AM CST

VTAE: 15.86 (-1.35)

Vitae Pharmaceuticals to Announce Third Quarter 2014 Financial Results on November 12, 2014
GlobeNewswire - Wed Nov 05, 5:30PM CST
Vitae Pharmaceuticals, Inc. (Nasdaq:VTAE), a clinical-stage biotechnology company, will host a conference call on Wednesday, November 12, 2014 at 4:30 p.m. EST to discuss third quarter 2014 financial results and recent operational highlights. A question-and-answer session will follow Vitae's remarks.
VTAE: 15.86 (-1.35)

Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Tue Oct 28, 11:46AM CDT

RGSE: 0.81 (-0.01), AMKR: 6.44 (unch), VTAE: 15.86 (-1.35), ASTI: 2.17 (+0.15), CLF: 10.58 (-0.13), LMNX: 18.22 (-0.29), IDTI: 17.64 (-0.11), HNR: 2.93 (-0.06), VDSI: 27.21 (+0.80), DCO: 24.82 (-0.32), MDCO: 24.54 (-0.73), SCYX: 9.30 (-0.18), VGGL: 3.12 (-0.38), RCPT: 111.30 (-0.13), IBIO: 1.12 (+0.01), SNY: 46.52 (-0.04), TWTR: 41.01 (-1.53), DPW: 1.66 (+0.03), MERU: 3.91 (-0.02), SANM: 24.83 (-0.23)

Market News: Apple Inc, Vitae Pharmaceuticals, Alexza Pharmaceuticals
at The Street - Mon Oct 27, 3:40PM CDT
Birinyi Associates president Laszlo Biriny opined that maybe the economy will catch up and the stock market may not have strong gains going forwardThe stock markets in the United States fluctuated on ...
VTAE: 15.86 (-1.35), AAPL: 112.61 (+1.36), ALXA: 1.61 (+0.01)

Vitae Pharmaceuticals Announces Exercise of Underwriters' Option to Purchase Additional Shares of Initial Public Offering
GlobeNewswire - Mon Oct 27, 3:10PM CDT
Vitae Pharmaceuticals, Inc. (Nasdaq:VTAE), a clinical stage biotechnology company, today announced that the underwriters of its previously announced initial public offering (IPO) of common stock have exercised in full their option to purchase 1,031,250 shares of common stock at the IPO price of $8.00 per share, less underwriting discounts. After giving effect to the over-allotment closing, the aggregate net proceeds to Vitae from the IPO, after underwriting discounts and commissions and estimated offering expenses, was approximately $56.0 million.
VTAE: 15.86 (-1.35)

Vitae Pharma up premarket on Phase 1 trial results
Seeking Alpha - at Seeking Alpha - Fri Oct 24, 8:31AM CDT

VTAE: 15.86 (-1.35)

Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Oct 24, 8:15AM CDT

AMZN: 316.09 (+4.58), SYNA: 62.00 (-1.19), FNFG: 7.75 (-0.03), VTAE: 15.86 (-1.35), VSR: 2.97 (-0.02), RMTI: 11.13 (-0.11), DRIV: 24.70 (+0.17), MXWL: 10.96 (+0.04), OXGN: 1.76 (+0.01), GIMO: 14.48 (-0.30), P: 18.53 (-0.26), APT: 2.85 (-0.15), BJRI: 46.36 (-0.99), LAKE: 11.40 (-0.84), IBIO: 1.12 (+0.01), KLAC: 79.57 (-0.16), DRYS: 1.39 (-0.04)

After Hour Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Oct 23, 4:42PM CDT

MXWL: 10.96 (+0.04), AMZN: 316.09 (+4.58), GIMO: 14.48 (-0.30), UFCS: 29.30 (-0.65), ABG: 74.30 (-1.70), P: 18.53 (-0.26), SYNA: 62.00 (-1.19), RUBI: 13.14 (+0.05), VTAE: 15.86 (-1.35), KLAC: 79.57 (-0.16)

Positive Top-Line Results Achieved From Two Phase 1 Clinical Trials of BACE Inhibitor BI1181181/VTP-37948 in Alzheimer's Disease
GlobeNewswire - Thu Oct 23, 3:10PM CDT
-- BI1181181/VTP-37948 Demonstrated Greater Than 80% Reduction of an Alzheimer's Disease Biomarker, the Cerebral Spinal Fluid Amyloid Beta Levels
VTAE: 15.86 (-1.35)

Vitae Pharmaceuticals Announces Closing of Initial Public Offering
GlobeNewswire - Mon Sep 29, 10:29AM CDT
Vitae Pharmaceuticals, Inc. (Nasdaq:VTAE), a clinical stage biotechnology company, today announced the closing of its initial public offering of 6,875,000 shares of common stock at an initial public offering price of $8.00 per share. The aggregate net proceeds to Vitae, after underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $48.4 million. As previously reported, Vitae Pharmaceuticals has granted the underwriters a 30-day option to purchase up to an additional 1,031,250 shares of common stock to cover over-allotments, if any, at the initial public offering price.
VTAE: 15.86 (-1.35)

CyberArk Soars 60% To Lead Post-IPO Trading Debuts
at Investor's Business Daily - Wed Sep 24, 2:41PM CDT
CyberArk Software soared 60% in first-day trading after its IPO priced above views, leading a group of new issues making their debuts Wednesday. The maker of security software designed to thwart cyberattacks, CyberArk Software (CYBR) priced 5.36...
ICL: 7.03 (-0.06), MDLY: 16.27 (-0.13), SFS: 14.27 (-0.31), JPM: 60.14 (-0.42), CYBR: 41.62 (+7.92), VTAE: 15.86 (-1.35), CFG: 23.66 (-0.20), RBS: 11.72 (-0.10), AAPL: 112.61 (+1.36), BABA: 115.20 (-3.00)

Vitae Pharmaceuticals Announces Pricing of Initial Public Offering
GlobeNewswire - Wed Sep 24, 8:25AM CDT
Vitae Pharmaceuticals, Inc., a clinical stage biotechnology company, today announced the pricing of its initial public offering of 6,875,000 shares of common stock at an initial public offering price of $8.00 per share. The shares are expected to begin trading on The NASDAQ Global Market on September 24, 2014 under the ticker symbol "VTAE." In addition, Vitae Pharmaceuticals has granted the underwriters a 30-day option to purchase up to an additional 1,031,250 shares of common stock to cover over-allotments, if any, at the initial public offering price.
VTAE: 15.86 (-1.35)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Step Inside Henson's Creature Shop Magic in NYC

Unlock Puppet Magic with Jim Henson Tours Puppet fans, let me tell you, there's something going on in Queens, NY that's got both nostalgia and innovation scribbled all over it. We're talking about the legendary Jim Henson's Creature Shop opening its doors. If you're looking to relive the magic that helped shape a generation, get ready to dive into a world where creativity...

Seismic Pharma Kicks Off Phase 3 Trial for Istaroxime

Seismic Sets the Stage for a Medical Milestone From the heart of biotech in Durham, North Carolina, seismic waves ripple through the medical community as Seismic Pharmaceuticals embarks on a high-stakes adventure. It's official: they've enrolled their very first patient in the global Phase 3 trial of istaroxime, targeting the grim specter known as cardiogenic shock. You...

Veteran Marketer Joins The Wisory's Advisory Board

Tyrrell Schmidt Joins The Wisory's Board Out of the blue, The Wisory has snatched Tyrrell Schmidt right off the retirement bench. This doesn't seem like just another board seating; it smells like a calculated power play. Schmidt, fresh from her heavyweight stint as Global CMO at TD Bank, adds a spicy dose of marketing prowess to The Wisory's already loaded Advisory Board....

BusyBee AI Revolutionizes Classroom Feedback Efficiency

Grading Overhaul: BusyBee's Role in Education Here's a twist for the history books: Agilix Labs' BusyBee, a slick AI assistant built right into the Buzz platform on Amazon Bedrock, is kicking traditional grading methods to the curb. This little helper is grading close to a million K-12 student submissions every month, meticulously approved by real teachers. Quite the...

OneAscent Welcomes Monica Stoudemire as New CCO

New Leadership in Compliance Diving straight into the tumultuous sea of securities compliance, OneAscent's got a fresh captain at the helm. Monica Stoudemire's stepped into the Chief Compliance Officer's shoes with a track record that'd make any investor breathe a sigh of relief. After all, blending two decades of on-the-ground experience with regulatory acumen ain't...

Helio Fred Garcia Honored by Diversity Action Alliance

Award Ceremony Set in the Big Apple In an industry where recognition often feels as transient as a ticker's daily high, the Diversity Action Alliance (DAA) is doing its bit to emphasize the lasting impact individuals can make. On September 16 in New York City, Helio Fred Garcia will be honored with the 2026 Pat Ford Larger Than Life Impact Award at the DAA's Annual...

Bitwise Pulls Plug on Dogecoin ETF Amid Market Risks

Bitwise Ditches Dogecoin ETF: End of a Speculative Era Who knew that a digital asset inspired by an internet meme would get a platform on Wall Street? Well, Bitwise did. They rallied behind Dogecoin, launching the Bitwise Dogecoin ETF, ticker BWOW. But as of September 10, 2026, the fund's journey is coming to an end with liquidation just around the corner. What Sparked...

Cannabis Industry Pushes for Robust Financial Services

Industry Gears Up for Financial Action Clearly, cannabis businesses are shouting louder than a vendor at a ballgame, demanding more than just the basic chips-and-soda banking service. They’re on the hunt for serious credit facilities, payments, and the traditional financial tools that most sectors take for granted. I mean, check this out: Shield Compliance just dropped...

K-9 Hero Act Aims to Ease Costs for Retired Dogs' Care

Let's Talk About the Loyalty that Dogs Deserve Who would've thought we'd be chatting about our four-legged heroes in a federal setting? But here we are, giving well-deserved attention to those furry federal agents. They're the ones who sniff out bombs and tackle crooks, and they're not asking for a retirement plan with a yacht – just some vet care! What the K-9 Hero Act...

AbbVie's Bold Leap in Menstrual Migraine Treatment

AbbVie's Game-Changing Atogepant Study When it comes to pushing boundaries in the pharmaceutical world, there's no sitting on the fence. AbbVie's Phase 3 LUNA study results are painting a bright picture for women who suffer from the relentless grip of menstrual migraines. In a world where not a single treatment option has been approved specifically for this condition,...